Nuclear Laser Medicine
dal 1986

40 di storia italiana
al servizio della diagnostica

ALFA-TALASSEMIA

L'**alfa-talassemia** è una delle più comuni emoglobinopatie nel mondo ed è causata dall'assenza o dalla ridotta sintesi di catene alfa-globiniche.

TARGET AC099

STRIP A

Red Marker Line

Control

1- PCR control A1
2- PCR control A2
3- PCR control A3

4- M -3.7 (NG_000006.1:g.34164_37967del3804)
5- M -4.2
6- M -20.5 (NG_000006.1:g.15164_37864del22701)
7- M --MED (NG_000006.1:g.24664_41064del16401)
8- M --SEA (NG_000006.1:g.26264_45564del19301)
9- M --FIL (NG_000006.1:g.11684_43534del31851)
10- M --CAL (NG_000006.1:g.8464_40664del32201)
11- M α1 cd 14 G>A (HBA1:c.44G>A)
12- M α1 cd 59 Hb Adana (HBA1:c.179G>A)
13- M α1 cd 47 Hb Hasharon (HBA1:c.142G>C)

14- WT α1 cd 14 (HBA1:c.44G>A)
15- WT α1 cd 59 (HBA1:c.179G>A)
16- WT α1 cd 47 (HBA1:c.142G>C)

Blue Marker Line

STRIP B

Red Marker Line

Control

1- PCR control B

2- M anti 3.7
3- M α2 init cd (HBA2:c.2T>C)
4- M α2 cd 19 -G (HBA2:c.56delG)
5- M α2 IVS1 -5nt (HBA2:c.95+2_95+6delTGAGG)
6- M α2 cd 59 Hb Adana (HBA2:c.179G>A)
7- M α2 cd 125 Hb Quong Sze (HBA2:c.377T>C)
8- M α2 cd 142 Hb Constant Spring (HBA2:c.427T>C)
9- M α2 cd 142 Hb Icaria (HBA2:c.427T>A)
10- M α2 cd 142 Hb Pakse (HBA2:c.429A>T)
11- M α2 cd 142 Hb Koya Dora (HBA2:c.428A>C)
12- M α2 poly A-1(HBA2:c.*+94A>G)
13- M α2 poly A-2 (HBA2:c.*+92A>G)

14- WT α2 init cd (HBA2:c.2T>C)
15- WT α2 cd 19 (HBA2:c.56delG)
16- WT α2 IVS1 (HBA2:c.95+2_95+6delTGAGG)
17- WT α2 cd 59 (HBA2:c.179G>A)
18- WT α2 cd 125 (HBA2:c.377T>C)
19- WT α2 cd 142 8M=9M=10M=11M
20- WT α2 poly A 12M=13M

Blue Marker Line

8M=9M=10M=11M = HBA2:c.427T>C, HBA2:c.427T>A, HBA2:c.429A>T, HBA2:c.428A>C
12M=13M = HBA2:c.*+94A>G, HBA2:c.*+92A>G

CARATTERISTICHE

Tecnologia
Ibridazione inversa su striscia

Materiale di partenza
Sangue intero (EDTA o citrato)

Nome	Codice
ALFA GLOBINA TEST	AC099

10 TEST

CE 0123 IVD

TARGET AC091

Red Marker Line (top)

Conjugate control

PCR control

1-M.-101C>T (HBB:c.-151C>T)
2-M.-92 C>T (HBB:c.-142C>T)
3-M.-87 C>G (HBB:c.-137C>G)
4-M.-30 T>A (HBB:c.-80T>A)
5-M.cod.5 –CT (HBB:c.17_18delCT)
6-M.cod.6 G>A (HbC) (HBB:c.19G>A)
7-M.cod.6 A>T (HbS) (HBB:c.20A>T)
8-M.cod.6 –A (HBB:c.20delA)
9-M.cod.8 –AA (HBB:c.25_26delAA)
10-M.cod.8/9 +G (HBB:c.27_28insG)
11-M.cod.30 G>C (HBB:c.92G>C)
12-M.IVS 1.1 G>A (HBB:c.92+1G>A)
13-M.IVS 1.2 T>A (HBB:c.92+2T>A)
14-M.IVS 1.5 G>C (HBB:c.92+5G>C)
15-M.IVS 1.6 T>C (HBB:c.92+6T>C)
16-M.IVS 1.110 G>A (HBB:c.93-21G>A)
17-M.IVS 1.116 T>G (HBB:c.93-15T>G)
18-M.IVS 1-25 (HBB:c.93-22_95del)
19-M.cod.39 C>T (HBB:c.118C>T)
20-M.cod.44 –C (HBB:c.135delC)
21-M.cod.76 –C (HBB:c.230delC)
22-M.IVS 2.1 G>A (HBB:c.315+1G>A)
23-M.IVS 2.654 C>T (HBB:c.316-197C>T)
24-M.IVS 2.745 C>G (HBB:c.316-106C>G)
25-M.IVS 2.844 C>G (HBB:c.316-7C>G)

26-W.-101 (HBB:c.-151C>T)
27-W.-92 to -87 (2M=3M)
28-W.-30 (HBB:c.-80T>A)
29-W.cod.5 to 9 (5M=6M=7M=8M=9M=10M)
30-W.cod.30 to IVS 1.6 (11M=12M=13M=14M=15M)
31-W.IVS 1.110 to IVS 1-25 (16M=17M=18M)
32-W.cod.39 (HBB:c.118C>T)
33-W.cod.44 (HBB:c.135delC)
34-W.cod.76 (HBB:c.230delC)
35-W.IVS 2.1 (HBB:c.315+1G>A)
36-W.IVS 2.654 (HBB:c.316-197C>T)
37-W.IVS 2.745 (HBB:c.316-106C>G)
38-W.IVS 2.844 (HBB:c.316-7C>G)

Blue Marker Line (bottom)

(2M=3M)= (HBB:c.-142C>T)= (HBB:c.-137C>G)
(5M=6M=7M=8M=9M=10M)= (HBB:c.17_18delCT)=(HBB:c.19G>A)=(HBB:c.20A>T)= (HBB:c.20delA)= (HBB:c.25_26delAA)= (HBB:c.27_28insG)
(11M=12M=13M=14M=15M)= (HBB:c.92G>C)= (HBB:c.92+1G>A)= (HBB:c.92+2T>A)= (HBB:c.92+5G>C)= (HBB:c.92+6T>C)
(16M=17M=18M)= (HBB:c.93-21G>A)= (HBB:c.93-15T>G)= (HBB:c.93-22_95del)

TARGET AC104

Red Marker Line (top)

Conjugate control

PCR Control

1-M. anti 3.7

2-M. -86 C>A (HBB:c.-136C>A)
3-M. -29 A>G (HBB:c.-79 A>G)
4-M. cap+1 A>C (HBB:c.-50A>C)
5-M. cap+33 C>G (HBB:c. -18 C>G)
6-M. HbG-San José (HBB:c.23A>G)
7-M. HbD-Ouled Rabah (HBB:c.60 C>A)
8-M. HbE (HBB:c.79G>A)
9-M. HbG-Copenaghen (HBB:c.142 G>A)
10-M. Hb Camperdown (HBB:c.315 G>C)
11-M. HbD-Punjab (HBB:c.364 G>C)
12-M. Hb O-Arab (HBB:c.364 G>A)
13-M. Hb Neapolis (HBB:c.380 T>G)
14-M. Hb Lepore-BW (NG_000007.3:g63632_7104del)
15-M. Siciliana (δβ)0 (NG_000007.3:g.64336_77738del13403)

16-W. -86 (HBB:c.-136C>A)
17-W. -29 (HBB:c.-79 A>G)
18-W. cap+1 (HBB:c.-50A>C)
19-W. cap+33 (HBB:c. -18 C>G)
20-W. HbG-San José (HBB:c.23A>G)
21-W. HbD-Ouled Rabah (HBB:c.60 C>A)
22-W. HbE (HBB:c.79G>A)
23-W. HbG-Copenaghen (HBB:c.142 G>A)
24-W. Hb Camperdown (HBB:c.315 G>C)
25-W. HbD-Punjab= Hb O-Arab (11M=12M)
26-W. Hb Neapolis (HBB:c.380) T>G)

Blue Marker Line (bottom)

11M=12M= (HBB:c.364 G>C)= (HBB:c.364 G>A)

CARATTERISTICHE

Tecnologia

Ibridazione inversa su striscia

Materiale di partenza

Sangue intero (EDTA o citrato)

Nome	Codice
BETA GLOBINA TEST	AC091
BETA GLOBINA PLUS TEST	AC104

20 TEST

NUCLEAR LASER MEDICINE S.R.L.
Viale delle Industrie, 3
20049 Settala (Milano) - ITALIA
TEL. 02 952451 - FAX 02 95245237.8
segreteria@nlm.it - **www.nlm.it**

www.nlm.it

MAGGIO 2026